The FTC filed a complaint against the specialty healthcare company that alleges that Endo and other companies used "pay-for-delay settlements" to restrict customers' ability to buy generic versions of its drugs.
The lawsuit alleges that Endo and its partners paid WatsonLaboratories hundreds of millions of dollars in exchange for the company's agreement not to market a generic version of Endo's Liboderm patch.
Endo "illegally maintained its monopoly over Lidoderm," the FTC said in a statement on Thursday.
"The FTC is seeking a court judgment declaring that the defendants' conduct violates the antitrust laws, ordering the companies to disgorge their ill-gotten gains, and permanently barring them from engaging in similar anticompetitive behavior in the future," the FTC said in a statement.
Separately, recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.
TheStreet Ratings rates this stock as a "sell" with a ratings score of D+. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity and generally disappointing historical performance in the stock itself.
You can view the full analysis from the report here: ENDP